Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Br Med Bull ; 119(1): 37-48, 2016 09.
Article in English | MEDLINE | ID: mdl-27325208

ABSTRACT

INTRODUCTION OR BACKGROUND: Small-cell lung cancer (SCLC) represents ~15% of all cases of lung cancer and is characterized by a rapid tumour doubling time, early onset disease dissemination and high sensitivity to chemotherapy. SOURCES OF DATA: We searched MEDLINE and OVID databases for articles in English published from January 1980 to February 2015. AREAS OF AGREEMENT: Platinum-based chemotherapy, thoracic radiotherapy and prophylactic cranial irradiation are standard of care. Benefit from second-line chemotherapy is limited. AREAS OF CONTROVERSY: The role of platinum/irinotecan chemotherapy in the Western population and the role of maintenance therapies remain to be established. GROWING POINTS: Knowledge of the biology of SCLC has expanded exponentially and many potential therapeutic targets have been identified. AREAS TIMELY FOR DEVELOPING RESEARCH: The use of circulating tumour cells can help investigating molecular alterations occurring within tumour cells, understanding drug resistance mechanisms and evaluating new treatments.


Subject(s)
Brain Neoplasms/prevention & control , Cisplatin/therapeutic use , Cranial Irradiation/methods , Lung Neoplasms/therapy , Platinum Compounds/therapeutic use , Small Cell Lung Carcinoma/therapy , Antineoplastic Combined Chemotherapy Protocols , Brain Neoplasms/secondary , Chemoradiotherapy/trends , Combined Modality Therapy , Cranial Irradiation/trends , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Neoplasm Recurrence, Local , Neoplasm Staging , Organ Sparing Treatments/methods , Organ Sparing Treatments/trends , Small Cell Lung Carcinoma/mortality , Small Cell Lung Carcinoma/pathology , Survival Analysis , Treatment Outcome , United Kingdom
2.
Cancer Treat Rev ; 41(5): 401-11, 2015 May.
Article in English | MEDLINE | ID: mdl-25842168

ABSTRACT

During the last decade, thoracic oncology has witnessed an unprecedented outburst of knowledge regarding molecular biology of non small-cell lung cancer (NSCLC). The implementation of high-throughput sequencing analysis and genomic technologies has led to the identification of novel molecular events that characterize NSCLC transformation and may represent critical oncogenic drivers amenable to targeted therapy. Among these, the presence of activating mutations of the epidermal growth factor receptor (EGFR) gene and of chromosomic rearrangements in the anaplastic-lymphoma kinase (ALK) proto-oncogene, have been the first well characterized genetic alterations with corresponding targeted agents to enter the clinical arena. Nevertheless, in the recent years a number of other oncogenic drivers beyond EGFR and ALK inhibition have emerged as novel molecular targets with potential therapeutic implications, including mutations in the genes KRAS, BRAF, HER2, PI3KCA and DDR2, as well as ROS1 and RET rearrangements and MET, HER2 and FGFR1 gene amplifications. The aim of this review is to provide comprehensive information on the novel therapeutic targets identified by recent preclinical evidence and to discuss developments in molecular treatments targeting these oncogenic drivers or actionable mutations beyond EGFR and ALK in advanced NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Lung Neoplasms/genetics , Molecular Targeted Therapy , Anaplastic Lymphoma Kinase , Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Genes, erbB-1 , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Proto-Oncogene Mas , Receptor Protein-Tyrosine Kinases/genetics
3.
Drugs ; 72(4): 471-90, 2012 Mar 05.
Article in English | MEDLINE | ID: mdl-22356287

ABSTRACT

Small cell lung cancer (SCLC) represents approximately 13% of all lung cancer diagnoses and the incidence has reduced over the last 20 years. Treatment of SCLC remains challenging because of its rapid growth, early dissemination and development of drug resistance during the course of the disease. Chemotherapy remains the cornerstone of treatment for limited (LD) and extensive disease (ED), with concurrent chemotherapy and radical thoracic radiotherapy representing the best treatment option for fit patients with LD. Platinum-based chemotherapy is the treatment of choice in fit patients with good organ function, and the radiosensitizing effect of cisplatin is critically important for concurrent chemoradiotherapy in LD. Anthracycline-containing regimens represent a viable alternative for patients where platinum-based chemotherapy is contraindicated. Patients who relapse or progress after first-line chemotherapy have a very poor prognosis. Second-line therapy may produce a modest clinical benefit. Maintenance chemotherapy has not been shown to convincingly improve outcomes for SCLC. A number of targeted agents have been investigated in LD and ED, mostly in unselected populations, with disappointing results. Prophylactic cranial irradiation has been shown to reduce the incidence of brain metastases and prolong survival for both LD and ED without negative impact on quality of life (QOL) and cognitive function. Ongoing trials will shed some light on the impact of thoracic radiotherapy on QOL, symptom control and survival in ED SCLC patients who benefitted from first-line chemotherapy.


Subject(s)
Lung Neoplasms/therapy , Small Cell Lung Carcinoma/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Drug Resistance, Neoplasm/drug effects , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Quality of Life , Radiotherapy, Adjuvant , Small Cell Lung Carcinoma/drug therapy , Small Cell Lung Carcinoma/radiotherapy
4.
Ther Adv Med Oncol ; 2(1): 25-37, 2010 Jan.
Article in English | MEDLINE | ID: mdl-21789124

ABSTRACT

Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease.

SELECTION OF CITATIONS
SEARCH DETAIL
...